Estrogen Treatment in Infertile Women with Premature Ovarian Insufficiency in Transitional Phase: a Retrospective Analysis
Overview
Reproductive Medicine
Authors
Affiliations
Purpose: During the transitional phase of premature ovarian insufficiency (POI), sporadic resumption of ovulation is possible because of fluctuation of hormonal levels but the chance of spontaneous pregnancy is low, and the main perspective of childbearing in these women is egg donation or adoption. The purpose of the study was to verify whether treatment with estrogens in POI patients in transitional phase could reduce FSH levels and to evaluate if this pre-treatment could improve reproductive outcomes of in vitro fertilization (IVF).
Methods: Study patients (26) were administered with valerate estradiol 2 mg daily adding dihydrogesterone 10 mg daily during luteal phase for 3 months before IVF. Control group (26 patients) did not receive any pre-treatment. Ovarian stimulation was conducted in both groups with the same short GnRH-antagonist protocol. Clinical and laboratory data of patients were retrospectively analyzed.
Results: In the study group, 4/26 POI patients became spontaneously pregnant during pre-treatment. In the remaining patients, the mean level of FSH after the pre-treatment was significantly reduced compared with baseline. Levels of circulating estradiol on the day of hCG administration were significantly higher in the study group. The total number of MII oocytes retrieved and fertilized oocytes was significantly higher in the study group, as well as the number of embryos transferred for pickup and clinical pregnancy rate.
Conclusions: Treatment with estrogens in infertile POI patients in transitional phase reduces circulating FSH levels, hence causing potential spontaneous conception. Moreover, in these patients, estrogen pre-treatment seems to improve IVF outcomes in a GnRH-antagonist short protocol compared to no pre-treatment.
Kakinuma K, Kakinuma T World J Clin Cases. 2024; 12(3):479-487.
PMID: 38322464 PMC: 10841946. DOI: 10.12998/wjcc.v12.i3.479.
Research progress on the premature ovarian failure caused by cisplatin therapy.
Li Z, Qi H, Li Z, Bao Y, Yang K, Min Q Front Oncol. 2023; 13:1276310.
PMID: 38053654 PMC: 10694504. DOI: 10.3389/fonc.2023.1276310.
Zhang L, Zou J, Wang Z, Li L Int J Mol Sci. 2023; 24(13).
PMID: 37445702 PMC: 10342156. DOI: 10.3390/ijms241310525.
Analysis of oxidative stress and antioxidative potential in premature ovarian insufficiency.
Kakinuma K, Kakinuma T World J Clin Cases. 2023; 11(12):2684-2693.
PMID: 37214574 PMC: 10198121. DOI: 10.12998/wjcc.v11.i12.2684.
Endocrine disorders and fertility and pregnancy: An update.
Bendarska-Czerwinska A, Zmarzly N, Morawiec E, Panfil A, Brys K, Czarniecka J Front Endocrinol (Lausanne). 2023; 13:970439.
PMID: 36733805 PMC: 9887196. DOI: 10.3389/fendo.2022.970439.